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Abstract 
St. Jude Medical: Pulmonary Edema Monitoring in Pacemakers and ICDs 
David Wei-Péng Chang 
 
Pulmonary edema occurs when fluid leaks from the pulmonary 
capillary network into the lung interstitium and alveoli.  When the heart is 
not able to pump blood to the body efficiently, fluid can back up into the 
veins that take blood through the lungs to the left atrium.  This then builds 
up the pressure in the blood vessels and fluid is pushed into the alveoli in 
the lungs.  The fluid reduces normal oxygen movement through the lungs 
and can cause impaired gas exchange and respiratory failure.  There are 
many causes of congestive heart failure that may lead to pulmonary 
edema such as heart attack, any diseases of the heart that weaken or 
stiffen the heart muscle, a leaking or narrowed heart valve, and sudden, 
severe high blood pressure.    
Pulmonary edema is a strong indicator of congestive heart failure in 
patients and therefore can be used as a gauge for congestive heart 
failure.  One way to diagnose cardiogenic pulmonary edema constantly is 
through the continuous monitoring of the transthoracic impedance 
throughout the day.  One method to achieve this constant monitoring is 
through the use of a cardiac pacemaker or an implantable cardioverter 
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defibrillator (ICD).  Many patients who are at risk of heart failure have 
these medical devices implanted already.  In these implantable cardiac 
devices, the connected cardiac leads can be utilized to continually screen 
several impedance vectors for decreases in impedance in the thoracic 
cavity.  A pacemaker or ICD that implements Pulmonary Edema 
Monitoring is designed to continuously monitor these impedance vectors 
and alert the patient to seek medical attention.   This thesis will discuss 
the implementation of Pulmonary Edema Monitoring via screening of 
multiple impedance vectors in a pacemaker or implantable cardioverter 
defibrillator and the effectiveness of this monitoring method.  Furthermore, 
the design, implementation, and testing of this feature will be explored in 
greater detail.    
 
 
Keywords: St Jude Medical, Implantable Cardioverter Defibrillators, 
Pacemakers, Medical Devices, Pulmonary Edema, Pulmonary Oedema, 
Congestive Heart Failure, Intrathoracic Impedance Monitoring. 
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Background and Clinical Significance 
 
Heart failure 
Heart failure (HF) is widely known as the leading cause of death for both 
men and women in the United States.  Approximately 600,000 people die of 
heart disease in the United States every year making the early detection and 
indication of heart failure a critical need [1].  Heart disease can be caused by 
many conditions such as coronary artery disease, heart attack, high blood 
pressure (hypertension), faulty heart valves, damage to the heart muscle 
(cardiomyopathy), myocarditis, heart defects (congenital heart defects), and 
abnormal heart rhythms.  Figure 1 displays the significant increase in heart 
disease in men and women as they grow older.  The percentage of men who 
report heart disease grows from just under 5% in the 18-44 year age range to 
approximately 45% in the 75 year and older age range.  The percentage of 
women who report heart disease grows from just under 5% in the 18-44 year age 
range to approximately 30% in the 75 year and older age range.   
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Figure 1: Respondent-reported lifetime heart disease prevalence among adults 18 years and over, by 
sex and age: United States, 1999-2009 [2] 
 
In addition, major heart failure events result in hospitalization with clinical 
manifestations of cardiogenic pulmonary edema including lab work, imaging 
chest x-rays (used to analyze pleural effusion and increased vascular 
congestion), echocardiograms, and invasive hemodynamic monitoring.  Major 
heart failure events can be confirmed by imaging and invasive monitoring and 
therapy.  These are all costly procedures to perform and are sometimes invasive 
to the patient.  The costs associated with heart failure amounted to an 
astonishing $29 billion in medical costs in 2004 [3].  A decreased frequency of 
hospitalization improves patients’ quality of life and may improve patient survival.  
For these reasons, heart failure is widely studied and monitored closely in 
patients at risk of heart failure.  Utilizing pulmonary edema as an indicator that 
3 
 
heart failure is a potential threat in the immediate future is a useful way of alerting 
patients to life threatening conditions before they occur.   
 
Pulmonary Edema (or Pulmonary Oedema) 
Pulmonary edema (PE) has several causes, such as lung infections, 
exposure to toxins, kidney disease, adverse drug reactions, smoke inhalation, 
acute respiratory distress syndrome (ARDS), or high altitude exposure.  
Congestive heart failure (CHF) is an imbalance in pump function in which the 
heart fails to maintain appropriate blood circulation.  The severest form of CHF is 
cardiogenic pulmonary edema (PE).   
A normal heart is composed of two upper chambers, called atria, and two 
lower chambers, called ventricles.  The atria receive incoming blood and pump 
the blood into the ventricles.  The ventricles are the more muscular chambers 
that pump the blood out of the heart.  Here in the heart, deoxygenated blood from 
the entire body flows into the right atrium and then is passed into the right 
ventricle.  The right ventricle then pumps the blood through the pulmonary 
arteries to the lungs.  In the lungs, the blood will release carbon dioxide and pick 
up oxygen.  The oxygen-rich blood returns to left atrium of the heart through the 
pulmonary veins and then is passed to the left ventricle.  From here, the blood is 
pumped out of the left ventricle through the aorta into the entire body.   
In a heart where pulmonary edema develops, the imbalance in pump 
function causes an increase in lung fluid secondary to leakage from pulmonary 
capillaries into the interstitium and alveoli of the lungs.  This fluid buildup in the 
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alveoli makes it difficult to breathe, leads to impaired oxygen and carbon dioxide 
gas exchange, and may cause respiratory failure.   As seen in Figure 2, clear 
alveoli allow for the constant flow of oxygen and carbon dioxide through the 
lungs.  In the case of pulmonary edema, the fluid buildup takes away from the 
alveoli surface area and disrupts the gas exchange of oxygen and carbon 
dioxide.   
 
 
Figure 2: Fluid may build up in the alveoli or leak into the tissues around the bronchioles. [4] 
 
This thesis will focus on heart-related cardiac pulmonary edema.  Cardiac 
pulmonary edema arises when a diseased or overworked left ventricle is not able 
to pump out enough of the blood it receives from the lungs.  As a result, pressure 
increases inside the left atrium and then in the veins and capillaries in the lungs.  
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This results in another imbalance of Starling forces in the lungs and then causes 
fluid to be pushed through the capillary walls into the air sacs.  When fluid builds 
up in the chest cavity, impedance decreases.  This impedance decrease can be 
measured by pacemaker or ICD leads.  Pulmonary edema is a serious condition 
and can cause death in as little as 60 minutes if left untreated.   Figure 3 shows 
the progression of congestive heart failure and pulmonary edema as previously 
described.     
 
 
Figure 3: Pulmonary and Cardiac Edema progression. [5] 
 
Pacemakers and Implantable Cardioverter Defibrillators (ICDs) 
Pacemakers are small pacing pulse generators that are implanted under 
the skin, most often just under the collarbone.  One or two lead wires will connect 
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the heart muscle to the pulse generator.  These pacemakers then use leads that 
are directly implanted into the heart to send electrical signals to start or regulate 
a heart rhythm.  A pacemaker may be used to replace the functionality of a 
heart’s natural pacemaker (the SA node) that is no longer functioning properly 
and has developed an abnormal heart rate or rhythm or in the case where the 
electrical pathways of the heart are blocked.   
Implantable cardioverter defibrillators (ICDs) are very similar to 
pacemakers, but have an extra shocking capability.  ICDs are capable of 
providing two levels of electrical energy to the heart: a low energy shock that can 
depolarize a heart causing it to beat, and a high energy shock that is delivered 
only if an arrhythmia is so severe that the heart is quivering instead of pumping 
or beating efficiently.  In addition to all of the components that make up a 
pacemaker, the ICD system also contain a pulse generator and extra leads to 
deliver the high energy shock.   
 The most common method for implanting one of these medical devices is 
through the endocardial (transvenous) approach.  In this method a local 
anesthetic is given to numb the implant area.  An incision is made in the upper 
chest region where the leads and pacemaker are inserted.  These leads are 
inserted through the incision made in the chest and the subclavian vein and are 
then guided to the appropriate chamber of the heart with the aid of a fluoroscopy 
machine.  The lead tip is lodged in and attached to the heart muscle, while the 
other end of the lead that is attached to the pacemaker or ICD is coiled around 
and placed in a pocket created under the skin in the upper chest.   
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Figure 4 shows both an ICD and pacemaker implant in a patient and how 
each is set up inside the patient.   Figure A of Figure 4 shows an implantable 
cardioverter defibrillator implanted in the upper chest of the patient.  Figure B of 
Figure 4 shows a pacemaker implanted in the upper chest.  For each device, the 
wires with electrodes on the ends are inserted into the heart through the 
subclavian vein in the upper chest as previously described [6].   
 
 
Figure 4: Placement of ICDs and pacemakers in the upper chest of patients [6]. 
 
With the use of up to six vectors, the pacemaker and ICDs can be used to 
take impedances across the intrathoracic cavity.  The different lead 
configurations allow for these medical devices to measure impedances across 
different impedance vectors.  By observing these impedances, these medical 
devices can detect when there is fluid buildup and thus be utilized to alert the 
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patient of potential heart failure.  Moreover, since many patients who are at risk 
of heart failure already have pacemakers or ICDs and the expanded capability of 
monitoring for pulmonary edema becomes a very useful feature to add on.  
These devices could be used to monitor impedance automatically and 
periodically.  Figure 5 depicts a high level concept of the use of a pacemaker or 
ICD and their leads to take impedances in the thoracic cavity.  This will aid in the 
monitoring of impedance drops due to fluid buildup in the chest region [7].   
 
 
Figure 5: A high level depiction of a pacemaker or ICD taking an impedance measurement. [7] 
 
A prospective study was performed with 34 patients with New York Heart 
Association class III or IV heart failure symptoms who were followed up for a 
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length of two years for heart failure hospitalization [8].  During heart failure 
hospitalization, most patients underwent invasive right-sided heart catheterization 
that enabled correlation of acute hemodynamic and impedance changes.  Once 
treatment of heart failure was initiated, impedance increased and correlated well 
with decreases in pulmonary capillary wedge pressure and net fluid loss.  With a 
threshold value of 60 Ω-days, sensitivity to predict heart failure hospitalization 
was 76.9%, with 1.5 false positive readings per patient-year.  Early warning 
criteria were met 13.4 ± 6.2 days (5 to 22 days) before hospitalization [8].  In a 
larger prospective study, a similar pulmonary edema monitoring algorithm in 
pacemakers and ICDs was used in patients who underwent biventricular ICD 
implantation.  The end point of that study was deterioration of heart failure on the 
basis of clinical assessment.  Patients were notified by an audible alert when the 
fluid index threshold was crossed and were examined in an outpatient clinic for 
further evaluation.  Data from 373 subjects were analyzed and showed that the 
algorithm had a 60% sensitivity (with 95% confidence interval 46% to 73%) factor 
and a positive predictive value of 60% (with 95% confidence interval 46% to 
73%) to predict heart failure events within at least 2 weeks [9].   
Another prospective single-center study with 115 patients that had 
congestive heart failure showed that 67% of alerts were false-positives if the fluid 
index threshold level was left at nominal settings (60 Ω-days).  Analysis of the 
data suggested that perhaps a higher fluid index threshold level should be used 
(100 to 120 Ω-days) to enhance specificity and maintain reasonable sensitivity 
(60% and 73%, respectively) [10].  Thus, the limitations of this system remain its 
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relatively low sensitivity and specificity.  On the other hand, interpretation of 
false-positive alerts is not straightforward, because these alerts may identify 
subclinical heart failure exacerbation or other clinically important problems, 
including pneumonia or exacerbation of chronic obstructive pulmonary disease.  
The question of whether clinical outcome can be improved by early intervention 
based on changes in thoracic impedance is currently being investigated in large 
multicenter trials [11].  These studies also display that it is conceivable that 
impedance measurements from other leads or a combination of leads may yield 
improved results.  There are promising experimental data to suggest that the 
addition of a left ventricular lead to the measurement vector could enhance 
specificity [12].   
Figure 6 further depicts the results of this study and how a pulmonary 
edema monitoring algorithm is beneficial to patients.  The graphs in Figure 6 
depict thoracic impedance measurements in a heart failure patient utilizing 
Medtronic’s OptiVol algorithm.  The fluid status trend was obtained from a patient 
with severe heart failure and frequent heart failure exacerbations over a 12-
month period. The top graph shows a decrease of daily impedance value below 
reference summed and expressed as fluid index. The bottom graph shows 
variations of daily impedance measurements in the black line and reference 
impedance values in the gray line.  When the patient was found to have 
worsened heart failure in the chronic heart failure clinic at point A, diuretic drugs 
were increased.  He remained clinically stable until June 2009 at point B, when 
he was admitted to an outside hospital for fluid overload.  He decompensated 
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again at point C, but responded to outpatient diuretic drugs.  More recently at 
point D, he was found to have a 6-pound weight gain.  Decline of transthoracic 
impedance was evident at the time of decompensation, with rebound after 
diuresis.  In this patient, setting the fluid index threshold to 80 to 100 Ω-days 
would likely be specific and sensitive enough to warn against impending 
exacerbations of heart failure [8]. 
 
 
Figure 6: These graphs depict thoracic impedance measurements in a heart failure patient [8].  
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Objectives 
 
Project Objective 
The main objective of this thesis is to implement an algorithm for 
pacemakers and ICDs that will automatically and periodically monitor the thoracic 
cavity for drops in impedance indicating possible pulmonary edema.   The 
implementation will be based on a wealth of research done by St. Jude Medical 
and other research papers and then outlined here.  Constantly examining 
electrical impedance measurements across the lungs, these implanted medical 
devices can detect fluid in the lungs and early signs of cardiac failure.  Long term 
monitoring of PE using impedance measurements can provide an early warning 
of fluid volume changes in the body.  These changes can be detected hours or 
days prior to hospital admission so that medical intervention can occur before 
symptoms reach a critical level.   
The theory is that as fluid builds up in the lungs the impedance drops.  
The pulmonary edema monitoring algorithm can be on or off and will utilize five to 
six vectors across pacing and shocking leads.  Furthermore, the feature can be 
programmed to monitor the patient at several different programmable, periodic 
time intervals.  This allows the physician to allocate more or fewer resources to 
monitor the status of fluid levels in the thoracic cavity.   
The ultimate goal of the PE impedance algorithm is to be able to predict 
when a congestive heart failure is about to occur.  A device based algorithm that 
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could instruct the patient or physician to intervene early, before symptoms have 
developed, could avoid the need for hospitalization.   
 
Project Requirements 
The main objectives of this thesis are to describe a method of: 
1. Automatically and periodically monitoring for decrease in impedance that 
might indicate an early onset of congestive heart failure.   
2. Measuring impedance accurately across the thoracic cavity for fluid 
fluctuations.  An average sensitivity of 50% or higher is desired.   
3. Minimizing the amount of false positives in the algorithm.  A false 
excursion rate (FER) of less than 1 false positive per year is desired.   
4. Storing long and short term averages as a reference point to indicate 
whether impedance is decreasing.   
5. Alerting the patient of potential congestive heart failure when the 
pacemaker or ICD determines a decline in impedance relative to long and 
short term averages.   
 
Project Theory 
 Body fluids are good conductors of electricity.  With this property, 
pacemakers and ICDs can use impedance checks to give an indication of how 
much fluid is built up in the thoracic cavity.  Monitoring this thoracic impedance 
allows a pacemaker or ICD to determine if there is an increase in fluid in the 
lungs if there is a decrease in impedance.  Monitoring will be accomplished by 
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using up to six impedance vectors across pacemaker and ICD electrode points.  
A long term and short term average will be used as a reference for decreases in 
impedance.  Through these checks, these implanted medical devices will be able 
to alert the patient to the danger of congestive heart failure in the near future.   
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Design and Implementation 
 
Overview of Impedance Based Monitoring 
Impedance is constantly changing when measured across the chest 
between a pacing lead and pulse generator.  The rapid changes in impedance 
are related to the cardiac and respiratory cycles as more or less blood or air fills 
the tissue between the monitoring electrodes.  Less dynamic changes are seen 
when fluid accumulates in lung tissue.  However, as pulmonary edema develops 
and builds up fluid, conductance improves causing a decline in impedance in the 
thoracic cavity.  Therefore, the temporal changes and adequate filtering of the 
impedance signal not only allow the assessment of cardiac contractility or minute 
ventilation, but may also serve as a measure of changing fluid status.    
This theory has been applied in clinical practice and impedance vectors 
are utilized in many pacemakers and ICDs.   In one of the original studies using 
an ICD lead implanted in the RV apex, impedance was measured periodically 
between the RV ICD coil and left pectoral pulse generator with the minute 
ventilation sensor [8].  Constant current was applied between the electrodes with 
a measurement frequency of 16 Hz.  Measurements were averaged over a 2 
minute period, and multiple samples were acquired during the day.  A special 
algorithm was designed that plotted a slow-moving average of daily impedance 
values.  Daily impedances were then compared against the moving average, and 
the difference was expressed as a fluid index.  As pulmonary edema develops, 
daily impedance values decline and move away from the average values.  Once 
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the cumulative difference between the daily measurement and reference value 
reaches a programmable threshold, the detection criterion is met and a warning 
is delivered to the patient [13]. 
 
Fluid Index 
The main aspects of the algorithm are contained in the moving average 
integral (MA), the negative trend, and short and long term averages.  These 
portions of the algorithm are based on the assumption that the impedance 
decreases when the patient’s heart condition worsens due to fluid accumulation 
in the body.  All portions of this algorithm will be continuously running and has a 
number of programmable parameters, described in Table 1. 
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Parameter name Explanation Investigated values 
Long Average The length of the long term average 7, 12, 14, 21 and 28 days 
Short Average The length of the short term average 16 - 64 hours with a 4 
hours incremental step  
Hours Until Reset The number of continuous hours the short 
average has to be above or equal to the 
long average for the fluid index to be reset  
4 - 52 hours with a 4 hours 
incremental step 
Vector Which impedance signal or signals should 
be used when deriving the Fluid Index 
63 possible combinations 
between all the electrodes.  
Threshold The Fluid Index threshold by which a 
detection is made when the Fluid Index >= 
threshold 
Depends on the Fluid 
Index size. 
Time of day When, during the day, the impedance 
values are measured.  For example can be 
00-24, 08-22 (day time), 22-08 (night time). 
Entire day data, afternoon 
data  (12PM – 6PM), night 
time data (12AM – 5AM) 
Table 1: Parameter description used by all algorithms and what values were investigated.  
 
The pulmonary edema monitoring algorithm works when it chooses one or 
more impedance signals and then calculating and resetting the Fluid Index based 
on those signals.  This Fluid Index is compared against a programmable 
threshold.  If the Fluid Index exceeds the threshold for more than 24 hours, then 
detection (excursion) is made.  This is also illustrated in Figure 7.  The first step 
of the algorithm is to measure the impedance vectors and then add together the 
combined impedance weights.  From here the conductance and Fluid Index are 
calculated and then compared against the Fluid Index threshold.   
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Figure 7: This shows a high level diagram for the fluid index algorithm. [14] 
 
The calculation of the Fluid Index is shown in detail in Figure 8.  The flow 
chart describes the method used to calculate the Fluid Index.  When the short 
term average is smaller than the long term average (also called the reference 
value), a temporary variable (temp) is calculated.  This is implemented using 
short term sum and long term sum.  The value of the temporary variable is then 
weighted with the time from the previous impedance sample, and added to the 
Fluid Index.  Fluid Index cannot be negative in value.  Additionally, the Fluid 
Index is reset if the short average is greater than or equal to the long average for 
more than Hours Until Reset consecutive hours. [14] 
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Figure 8: This is the flow chart that describes the method used to calculate the Fluid Index.  
[Removed by SJM Legal] 
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Impedance vectors 
Impedance measurements are taken regularly at programmable intervals.  
The measurements will take 2 minutes for all 6 vectors and is conducted at a 16 
Hz frequency with the electrodes.  Since the impedance signals from each 
different vector vary in amplitude and variance, weighted averaging has been 
used to add vectors together.  The weighting factors are derived from the 
average and standard deviation of the impedance signals in the pulmonary 
edema monitoring feasibility study.  These values are shown in Table 2 [14]. 
 
  
RV coil – 
case 
LVr – 
RAr 
RVr – 
LVr 
LVr – 
case 
RAr – 
case 
RVr – 
case 
Average in data 58.95 Ω 605.91 Ω 563.28 Ω 396.60 Ω 287.59 Ω 249.09 Ω 
Standard 
deviation in data 
4.76 Ω 39.97 Ω 39.72 Ω 35.61 Ω 17.14 Ω 16.22 Ω 
Offset for mixing 58.42 606.44 564.28 395.65 287.55 248.63 
Scale factor for 
mixing 
4 32 32 32 16 16 
Table 2: This is a table of coefficients for weighting and adding vectors together. [14] 
 
The formula used for adding vectors is: 
)64032
_
(
1
,




N
i i
iio
s
factorscale
offsetZ
Z  
In this formula, N is the number of used vectors, Zs is the mixed impedance 
signal, Zo,i is the original impedance data for impedance vector i, offseti and 
scaled_factori are the offset and scale factor for vector i, the current vector of 
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choice.  The constant offset of 640 Ω is the constant value chosen to make the 
combined impedance a positive value, and the constant scaling factor of 32 Ω is 
chosen so that the scaled vector resembles a real vector.  In the calculated 
average and standard deviations, the standard deviation is approximately 5% of 
the average for all vectors.  Therefore, taking 5% of 640 Ω yield 32 Ω. [14] 
 
As an example of utilizing this algorithm, when the vectors RV coil to Case 
and RVr to Case are to be mixed, the formula will be:  
)64032
16
63.248
()64032
4
42.58
(
,, 



  caseRVrocaseRVcoilos
ZZ
Z  
If only a single vector is to be used, no scaling would have to be 
accounted for.  If a scaling factor is applied to the impedance signals as well as 
to the thresholds (apart from the Negative Trend algorithm), the algorithm output 
would be identical.  Thus, it is possible to change the scale factors by replacing 
them by shift operations to avoid division and keep resolution if the same scaling 
is applied to the thresholds as well (apart from the Negative Trend algorithm) 
[14]. 
Since the Negative Trend algorithm only counts the number of days the 
impedance is dropping, neither a scale factor nor an offset applied to the signals 
will have an effect on the threshold. This simplifies the calculations even further.  
Consequently for the Negative Trend algorithm, the example above could be 
reduced to: 
caseRVrocaseRVcoiloNTforchangeds ZZZ   ,,__, 28  
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Moving Average Integral 
The moving average (MA) integral algorithm integrates the difference 
between the short term and long term averages when the impedance is dropping.  
This integral constitutes the Fluid Index and therefore the algorithm takes both 
the size of the impedance drop and the length of the drop into account.  In the 
case where the short term average is greater than or equal to the long term 
average for a short period of time, the short term average is less than Hours Until 
Reset hours, the difference will be negative and the Fluid Index will decrease.   
Furthermore, a limit is set so the Fluid Index can never be below zero.   However, 
if the short term average has increased for more than Hours Until Reset hours in 
a row, the Fluid Index is reset to zero.  The short term and long term averages 
are calculated by taking the average of the impedance signal measured in the 
previous Short Average or Long Average days, respectively [14].   
  
Negative Trend 
The Negative Trend algorithm is a simple version of the above algorithms 
which simply counts the time the impedance has been dropping. The size of the 
drop is not important.  If the short term impedance average is less than the long 
term average, the Fluid Index is increased.  If the short term average is greater 
than or equal to the long term average for shorter periods of time (shorter than 
Hours Until Reset hours), the Fluid Index is decreased.  However, the Fluid Index 
never can be below zero.  If the short term average has been greater than or 
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equal to the long term average for more than Hours Until Reset hours 
continuously, the index is reset to zero.   
An example of how this algorithm works is shown in Figure 9.  From top to 
bottom panels in Figure 9: normalized impedance (combined vectors), short 
average (blue), and long average (red); patient symptoms; Fluid Index (blue) with 
a threshold (dashed line); excursions (black) & HF events (red).  In this figure, 
the excursion is a TP.  The very first heart failure event falls in the lead 
maturation period so that it is not detectable [14]. 
 
 
Figure 9: An example of Fluid Index (Negative Trend) for HF detection [14].  
  
* Vectors: RVc-Case + LVr-RAr +
RVr-Case
* Signal: Impedance
* Time of day: 0 to 24
* Algorithm: Negative trend 2
* Long average: 14 days
* Short average: 24 hours
* #hours to reset: 8 hours
* Threshold: 12.1096
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Patient Specific Threshold 
The majority of analyses for the algorithm were completed with a fixed 
threshold for all patients.  However, with patient specific threshold, further 
improvement could be achieved.  Patient specific threshold was evaluated based 
on cost saving.  For example, if a threshold other than the nominal for the 
particular patient could result in higher cost savings, the particular threshold 
value with optimized cost saving was determined as the specific threshold for 
that patient.  Using equal steps (of 0.1 day) between 10 and 20 days (this range 
was tested and found to be adequate to cover reasonable changes in the 
threshold) for threshold, the optimal threshold for the majority of patients stayed 
at the nominal threshold while optimizing threshold for the remaining patients 
could achieve better sensitivity and/or false excursion rate (FER) as shown in 
figures 10 and 11. [14]   
In figure 10, patient specific threshold histogram that gives optimal 
performance for cardiac resynchronization therapy defibrillator (or CRT-D) is 
shown.  53 out of 61 patients (87%) have optimal performance at the nominal 
threshold, and 8 (13%) benefit from changing the threshold.  Sensitivity remains 
the same (71.4%) and FER is improved from 0.56 to 0.14 with patient specific 
threshold. 
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Figure 10: Patient specific threshold histogram that gives optimal performance for cardiac 
resynchronization therapy defibrillator (or CRT-D).   
 
 In Figure 11, patient specific threshold histogram that gives optimal 
performance for an ICD is shown.  48 out of 61 patients (79%) have optimal 
performance at the nominal threshold, and 13 (21%) benefit from changing the 
threshold.  Sensitivity is improved from 61.9% to 76.2% and FER is improved 
from 0.63 to 0.21 with patient specific threshold. 
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Figure 11: Patient specific threshold histogram that gives optimal performance for an ICD.  
 
In reality, when one has programmable threshold values to accommodate 
specific patient needs, implementation would not be in fine steps of 0.1 day but 
rather coarse steps of 1 day (12 samples) except for the nominal and adjacent 
values, which would be rounded to the closest integer number of samples to 
achieve best performance in terms of cost saving.  For example, a non-integer 
day of threshold may be chosen to better incorporate most patients to have 
specific threshold change needed in fine steps.  With coarse steps, sensitivity 
and FER keep the same improvement as with fine steps except for FER for ICD, 
which is 0.24 instead of 0.21. The actual threshold (displayed both in days and 
number of samples) and the displayed threshold to the user on the programmer 
(displayed in days) are shown in the tables below.  In these tables only the 
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nominal threshold and the two adjacent thresholds have different actual and 
displayed values. 
 
CRT-D 
 Displayed threshold in 
days 
Actual threshold in days (# of 
samples) 
10 10 (120) 
11 11 (132) 
12 12 (144) 
13 13 (156) 
14 13.67 (164) – nominal 
15 14.7 (176) 
16 16 (192) 
17 17 (204) 
18 18 (216) 
19 19 (228) 
20 20 (240) 
Table 3: This table shows the displayed and actual programmable thresholds in coarse steps for a 
CRT-D device.   
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ICD 
 Displayed threshold in 
days 
Actual threshold in days (# of 
samples) 
10 10 (120) 
11 11 (132) 
12 11.7 (141)  
13 12.75 (153) – nominal 
14 13.9 (167) 
15 15 (180) 
16 16 (192) 
17 17 (204) 
18 18 (216) 
19 19 (228) 
20 20 (240) 
Table 4: This table shows the displayed and actual programmable thresholds in coarse steps for an 
ICD device.   
 
Patient Alert 
When the medical device confirms a decrease in the impedance in the 
intrathoracic cavity, the device shall trigger a clinical alert to be viewed by the 
doctor and a patient alert that will indicate to the patient that they need to see a 
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doctor immediately.  The patient alert will signal the patient via a 10 second 
vibrating notification from the medical device utilizing a vibrating motor.  A 
second vibrating signal will occur 30 seconds after the first alert as a confirmation 
of the alert to the patient.  After the initial pair of alerts, the device will continue to 
alert the patient once every hour until the patient notification alert is cleared by a 
physician.  This alert will serve to constantly warn the patient of a life threatening 
condition that is imminent.   
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Results 
 
Algorithm Optimization 
The results from a study performed by St. Jude Medical staff consisting of 
data on the combined pulmonary edema monitoring algorithms from June 2008 
are shown below.  Table 5 shows the settings that generate the best results 
according to the study discussed above for the different algorithm types [14].  In 
Table 5, the results show the optimal settings for the two different algorithm types 
and the performance of these in terms of sensitivity, false excursion rate (FER), 
and percent of event free duration spent in resolution (PEFDR).   Both parts of 
the algorithms show a sensitivity value of higher than 50%.  When looking at 
FER, the negative trend algorithm falls below 1 false positive per year, while the 
moving average algorithm is higher than the allowed 1 false positive per year.  
This shows that the use of the moving average by itself is not sufficient to fulfill 
the project goals.  However, the negative trend in conjunction with the moving 
average fulfills the project requirements set out in this thesis.  However, the 
moving average algorithm may not be sufficient to meet the project requirements 
and cannot be used individually without the negative trend algorithm.   
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Algorithm settings Results 
Algorithm 
name 
Vector 
Lon
g 
Ter
m 
Avg 
Short 
Term 
Avg 
Hours 
Until 
Reset 
Time 
of 
day 
Threshol
d 
Sensitivit
y 
FER  
(FP/year
) 
PEFDR 
Negative 
Trend 
RVc-Case 
+ LVr-RAr 
+ RVr-Case 
14 
days 
24 h 8 h 00-24 
12.1096 
 days 
79 % 0.84 98 % 
MA 
Integral 
LVr-RAr + 
RVr-LVr + 
LVr-Case + 
RVr-Case 
14 
days 
24 h 8 h 00-24 
100.8626 
Ω*days 
93 % 3.75 92 % 
Table 5: This table shows the optimal settings for the two algorithms [14]. 
 
The results for the negative trend algorithm for single impedance vector 
used were also obtained and displayed in Table 6.  Table 6 displays the 
algorithm and algorithm settings matched with the appropriate the results 
associated with each configuration.  Each vector shows a sensitivity of at least 
71% or higher.   However, the FER was far too high with vector yielding a result 
greater than 1.   
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Algorithm settings Results 
Algorithm 
name 
Vector 
Long 
Term 
Avg 
Short 
Term 
Avg 
Hours 
Until 
Reset 
Time 
of 
day 
Threshold Sensitivity 
FER  
(FP/year) 
PEFDR 
Negative 
Trend 
RVc-
Case 
21 
days 
48 h 8 h 00-24 
12.3188 
days 
71 % 1.3692 97 % 
Negative 
Trend 
LVr-
RAr 
7 days 24 h 8 h 00-24 
5.5813 
days 
93 % 4.81 94 % 
Negative 
Trend 
RVr-
LVr 
14 
days 
24 h 8 h 00-24 
9.7796 
days 
79 % 2.46 95 % 
Negative 
Trend 
LVr-
Case 
14 
days 
48 h 48 h 00-24 
11.7908 
days 
79 % 2.46 92 % 
Negative 
Trend 
RAr-
Case 
21 
days 
48 h 48 h 00-24 
5.5432 
days 
100 % 9.05 71 % 
Negative 
Trend 
RVr-
Case 
21 
days 
24 h 8 h 00-24 9.875 days 86 % 3.27 91 % 
Table 6: This table shows the optimal settings and performance for each of the six single vectors for 
the Negative Trend algorithm. [14] 
 
Table 7 shows the performance of the algorithm for ICD and CRT-D 
devices when combining vectors together [14].  Patients with bad vectors and 
patients with non-cardiac events were also included in the study.  The algorithm 
sensitivity decreases by approximately 10% when comparing to the performance 
from a single vector.  However, the overall performance remains above 50% 
sensitivity and FER of less than 1 FP/yr.  A negligible difference of 0.04 false 
positives per year for FER and 0.1 % for PEFDR is observed between the two 
devices.  This shows that both types of devices are reliable when utilizing a 
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combination of two vectors at a time to determine impedance decreases.  These 
results support the results shown in Table 5 as well.   
 
Algorithm Settings Results 
Device 
Type 
Vector Long 
Term 
Avg (hr) 
Short 
Term 
Avg (hr) 
Hours 
Until 
Reset 
Thresh
old 
(days) 
Sensitivit
y 
 
FER 
(FP/yr) 
PEFD
R (%) 
CRT-D RVc-Case 
+ LVr-
Case 
288 48 20 13.67 71.4 
 
0.56 
 
98.6 
ICD RVc-Case 
+ RVr-
Case 
336 28 8 12.75 61.9 0.6 98.5 
Table 7: This table shows the optimal settings and performance for different device types for the 
Negative Trend algorithm. [14] 
 
Lead Type 
 The study performed by St Jude Medical staff also detailed the lead types 
with the impedance range used.  The results display which pacemaker or ICD 
lead would yield the best results for the use of this algorithm.  St. Jude Medical 
QuickSite and QuickFlex leads were used in this study.  Combining US and non-
US patient data, there are a total of 86 patients implanted with QuickSite LV lead, 
two of which have saturated and invalid LVr-Can impedance values.  There are a 
total of 7 patients implanted with QuickFlex lead, two of which have high LVr-Can 
impedance values and a significant number of saturated samples.  However, 
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impedance of one of these patients recovered and became usable and valid.  In 
Table 5, it shows that 5 out of the 7 QuickFlex leads showed impedance in the 
normal range as compared to QuickSite leads.  [14] 
 
Point ID Lead 
With saturated 
samples? 
Z LVr_Can at the end of 
record 
1603 QuickSite Yes Saturated, > 750 ohm 
5303 QuickSite Yes Saturated, > 750 ohm 
205 QuickFlex No OK, ~ 500 ohm 
301 QuickFlex No OK, ~ 475 ohm 
302 QuickFlex No OK, ~ 300 ohm 
402 QuickFlex No OK, ~ 400 ohm 
2601 QuickFlex Yes OK, ~ 600 ohm 
2602 QuickFlex No OK, ~ 525 ohm 
2705 QuickFlex Yes Saturated, > 750 ohm 
Table 8: This table shows the lead types with the impedance range used for US and outside of the 
US patients. [14] 
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Discussion 
 
Strengths 
 There are several strengths to this approach of pulmonary edema 
monitoring.  The first and foremost important benefit of a pacemaker and ICD 
based algorithm is that many patients at risk of heart failure already have these 
devices implanted.  Since these medical devices are already implanted, it allows 
for expansion of use without the addition of other devices, surgery, or costly 
training.  It is easy to see that a simple algorithm update can add to the additional 
usefulness of patient monitoring.   
 Additionally, pacemakers and ICDs have a five to ten year battery life [15].  
This assures that pulmonary edema monitoring will be present during the time 
that these devices are implanted and operational.  Since the algorithm is not 
always on, the monitoring system would cost little battery life as well.   
 
Weaknesses 
 One of the weaknesses of this algorithm is that any complications arise 
from the implant and lead dislodgement would be difficult to troubleshoot.  Once 
implanted, it is difficult to reach the device and leads again to readjust the 
system.  Leads cannot be easily removed or repositioned without another costly 
surgery.  If either of these conditions were to occur, the pulmonary edema 
monitoring system would not be able to provide accurate feedback.   
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Furthermore, while the battery life is long at five to ten years as previously 
discussed, the negative aspect of this is that it would require another procedure 
to implant a replacement device when the battery is depleted.  The surgery and 
additional device does add a significant cost to the patient every five to ten years.  
Since patients with this condition are usually frail, it is optimal to minimize 
operations and medical procedures performed on them.  Any form of hardware 
update to this system would be cost inefficient or impossible without another 
device implant.  Software updates are easier and would only require a trip to the 
doctor’s office.   
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Conclusion and Future Work 
 
Conclusion 
 The implementation of the pulmonary edema monitoring algorithm is a 
large, successful step towards early detection of congestive heart failure.   The 
results show that this algorithm was successful in reaching the project objectives 
by fulfilling the requirements set out in this thesis.  The combination of the 
negative trend and moving average algorithms allow the pacemaker and ICD to 
automatically and periodically monitor for a decrease in impedance based on the 
programmed parameters set.  A sensitivity of 50% of higher was reached in all 
devices used.  The number of false positives per year was limited to less than 1 
per year.  The use of long term and short term averages were used as a 
reference point for the moving average algorithm.  Finally, the indication of any of 
these issues would trigger an alert to warn the patient of the potential life 
threatening condition.   
This thesis shows that the objectives set out for pacemakers and ICDs 
has been accomplished.  These pacemaker and ICD systems can be used to 
monitor the patient’s fluid levels and therefore detect the onset of congestive 
heart failure.  Utilizing impedance checks along with a short and long term slope 
comparison, these medical devices can check for fluid buildup accurately and 
constantly.  Being able to check the patient’s status constantly, periodically, and 
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automatically, pacemakers and ICDs provide an added safety measure to their 
original intent of pacing and shocking the heart.    
 
Future Work 
 This algorithm is promising technology to use in the constant monitoring 
and status of congestive heart failure.  However, there are a few other 
technologies or algorithms that could enhance this technology.   
One possible enhancement is the implementation of additional electrodes 
that would give the opportunity to sense from more locations for a more accurate 
reading.  At times when leads become dislodged from the heart, additional 
electrodes would provide a potential backup extra vector to replace the one that 
was lost due to dislodgement.  Additional vectors would also give the benefit of 
having a more precise way of measuring fluid in the chest cavity.   
Another enhancement is expanding the algorithm to include cardiogenic 
impedances in reference to the thoracic impedance currently monitored.  The 
addition of this trend with the thoracic impedance allows for a determination of 
whether the thoracic cavity of the patient generally has too much or too little fluid.  
This added algorithm change would give another measurement to improve the 
precision of detecting fluid buildup and congestive heart failure [16]. 
Furthermore, an additional improvement is the coupling of the pacemaker 
and ICD system to a drug therapy device.  In response to a drop in thoracic 
impedance, diuretics such as furosemide or bumetanide can be administered to 
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the patient to reduce this fluid buildup.  These extra medical devices allow for 
immediate treatment during onset of a pulmonary edema.   
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Acronyms and Definitions 
 
ICD – Implantable Cardioverter Defibrillator 
CRT-D – Cardiac Resynchronization Therapy Defibrillator 
PE – Pulmonary Edema 
CHF – Congestive Heart Failure 
HF – Heart Failure 
FI – Fluid Index 
MA – Moving Average 
FER – False Excursion Rate 
PEFDR – Percent of Event Free Duration spent in Resolution 
RV – Right Ventricle (Heart Chamber) 
LV – Left Ventricle (Heart Chamber) 
RA – Right Atrium (Heart Chamber) 
LA – Left Atrium (Heart Chamber) 
RVr – Right Ventricle ring (Electrode)  
LVr – Left Ventricle ring (Electrode) 
RAr – Right Atrium ring (Electrode) 
LAr – Left Atrium ring (Electrode) 
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